d. The prevalence of chronic heart failure (CHF) has reached
a pandemic level, and its further growth is projected. Commonly, the patients
with heart failure have a significant level of co-morbidities, and comorbidity
index increases with age. In such patients, it is important to avoid polypharmacy
to maintain a satisfactory adherence to the recommended treatment. Therefore,
it is better to choose drugs that act simultaneously on the common links in the
pathogenesis of CHF and other cardiovascular pathology. Use of sartans, which
affect the main pathogenetic links of both CHF and comorbid conditions, is
justified in terms of reducing the total number of drugs taken by the patient,
which, consequently, decreases the economic burden on the patient and improves
adherence to treatment. The latter, in turn, will help improve the quality of life,
reduce the number of hospitalizations and make the prognosis better.
The aim. To analyze the literature regarding valsartan to reveal its
benefits compared to other drugs affecting the renin-angiotensin-aldosterone
system activity in the treatment of the patients with CHF.
Materials and methods. A search and analysis of available literature
sources for the last 30 years in the PubMed database using a combination of
keywords "chronic heart failure", "valsartan", "sartan" was conducted.
According to the search results, 123 articles were selected for detailed analysis
